Histamine-Modulating Bacteria
Some gut bacteria reduce the effective Histamine load in the gut, supporting management of Histamine Intolerance and reducing one input to Total Mediator Load.
Common misconception
These bacteria are widely described as “histamine-degrading” in patient communities and some clinical literature. This implies they produce diamine oxidase (DAO) or otherwise enzymatically break down histamine directly. No published evidence supports this for the species listed below. What they actually do is modulate histamine signaling — downregulating histamine receptors, suppressing histidine decarboxylase expression, or shifting immune balance away from Th2/pro-allergic responses. The net clinical effect (reduced histamine symptoms) is real, but the mechanism is immunomodulatory, not enzymatic degradation. This distinction matters because it affects expectations about timing and dose-response.
Known Histamine-Modulating or Histamine-Neutral Species
- Bifidobacterium infantis — reduces histamine signaling by downregulating H1R and HDC expression in intestinal tissue (Dev et al., J Pharmacol Sci 2008, PMID 18544899). Anti-inflammatory. One of the most commonly recommended genera for histamine-sensitive individuals.
- Bifidobacterium longum — histamine-neutral to histamine-degrading
- Lactobacillus rhamnosus GG — histamine-neutral (does not produce histamine). Downregulates FcεRI and H4R expression on mast cells, reducing mast cell reactivity (Oksaharju et al., World J Gastroenterol 2011, PMID 21390145)
- Lactobacillus plantarum — generally histamine-neutral, some strains may reduce histamine levels through competitive metabolism
- Lactobacillus salivarius — histamine-neutral
Mechanism
These bacteria reduce histamine burden through indirect pathways rather than direct enzymatic degradation:
- Downregulation of host histamine receptor expression (H1R, H4R)
- Suppression of histidine decarboxylase (HDC) expression in intestinal tissue
- Competition with Histamine-Producing Bacteria for ecological niches
- Production of anti-inflammatory metabolites that shift immune balance
- Support of epithelial barrier integrity, reducing trigger exposure
Practical Application
When choosing probiotics in the context of mast cell conditions:
- Avoid strains known to produce histamine (see Histamine-Producing Bacteria)
- Favor Bifidobacterium-dominant formulations
- Research at the strain level when possible — species-level generalizations are insufficient
- Introduce slowly and monitor, because even theoretically safe strains can shift the microbiome in unpredictable ways
Supporting endogenous histamine-modulating bacteria through prebiotic fiber (feeding them) may be as important as introducing them through supplementation. See SCFAs and Butyrate.